Analysts fell to the sidelines weighing in on Demant (WILLF – Research Report) and Innate Pharma SA (IPHYF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Demant (WILLF)
Kepler Capital analyst Maja Pataki maintained a Hold rating on Demant on September 14 and set a price target of DKK295.00. The company’s shares closed last Tuesday at $44.00, equals to its 52-week high of $44.00.
According to TipRanks.com, Pataki is ranked #8442 out of 8566 analysts.
Demant has an analyst consensus of Moderate Buy, with a price target consensus of $44.22.
See the top stocks recommended by analysts >>
Innate Pharma SA (IPHYF)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on September 14 and set a price target of EUR3.10. The company’s shares closed last Thursday at $3.00.
According to TipRanks.com, Telliez is ranked #4643 out of 8566 analysts.
Innate Pharma SA has an analyst consensus of Hold, with a price target consensus of $3.32.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on WILLF:
- Demant upgraded to Outperform from Neutral at Oddo BHF
- Demant price target raised to DKK 297 from DKK 272 at Morgan Stanley
- Demant upgraded to Overweight from Neutral at JPMorgan
- Demant price target raised to DKK 295 from DKK 275 at Credit Suisse
- Demant price target raised to DKK 275 from DKK 265 at Barclays
